| Orchard Therapeutics [ORTX] - Last Close: $8.14 Orchard Therapeutics just landed a sweet deal. The tiny biotech has agreed to be acquired by Japan's Kyowa Kirin Co. in an all-cash deal valued at $387.4 million. Orchard Therapeutics investors will receive $16 for every common share, plus a contingent value rate for another $1 payment based on OTL-200's approval. Without the milestone payments, the purchase price represents a 96.5% premium compared to Wednesday's close. If the CVRs are triggered, the deal could be worth as much as $477.6 million. Shares of ORTX are up 96.5% in early premarket trading. My Take: ORTX is already trading in line with the purchase price. Shares are sitting at $16, so the only potential upside left is the $1 CVR payment, but I don't think the downside risk justifies the chase. Grom Social Enterprises [GROM] - Last Close: $1.75 Grom Social is rallying in today's premarket. The media company hasn't made any major announcements lately, but shares appear to be rebounding after a lengthy sell-off. Grom suffered steep losses in early September, after the company announced plans for a $3.0 million public offering. Since then, share prices have been steadily declining until this week. Over the past three days, GROM is beginning to rebound and volume is spiking. GROM Is one of the day's top premarket performers, with a 28.5% gain in early trading. My Take: GROM is flashing some very favorable technical signals. This could be a swing trade set up. Longeveron [LGVN] - Last Close: $2.51 Positive drug data is lifting shares of Longeveron. About an hour ago, the pharma firm announced positive top-line results from its CLEAR MIND Phase 2A trial for Lomecel-B™ Alzheimer's therapeutics. Longeveron said the study met its primary endpoint and was found to be safe across all study groups. The drug also met its secondary endpoint by achieving statistical significance, and Longeveron expects to release more biomarker data in the coming weeks. LGVN is up 33.4% on active trading volume in the premarket. My Take: LGVN is getting a boost from this news, but I saw some potential red flags in the press release. Be cautious because this rally could pull back at some point soon. Vivos Therapeutics [VVOS] - Last Close: $0.3045 Vivos Therapeutics is on my list for the second day in a row. The tiny healthcare company announced a new strategic collaboration in the Middle East-North Africa region to support its international expansion push. As part of the deal, Vivos has entered into an exclusive distribution agreement with Dubai-based NOUM DMCC, or Noum. Noum will receive exclusive rights to distribute Vivos' products in the region, including in Saudi Arabia, UAE, and other key markets. VVOS is up 23.7% on active trading volume. My Take: VVOS is on a tear. It rallied 64.5% on Wednesday, and it's extending its run in today's premarket. The chart is ugly, and the sudden volume spike seems suspect, but there's a slim chance this is a pivot point. GainersMeiwu Technologies [WNW] >> +69.9%HHL Acquisition [HHLA] >> +59.1%Cartesian Growth [RENE] >> +25.0% DeclinersCambium Networks [CMBM] >> (35.3%) Reservoir Media [RSVR] >> (25.0%)MaxCyte [MXCT] >> (19.5%) Constellation Brands, Inc. [STZ] ... AM
Lamb Weston Holdings, Inc. [LW] ... AM
Conagra Brands, Inc. [CAG] ... AM
Levi Strauss & Co [LEVI] ... PM
Aehr Test Systems [AEHR] ... PM
Park Aerospace Corp. [PKE] ... PM
Calamp Corp. [CAMP] ... PM Initial jobless claims [Sep] ... 8:30aU.S. trade deficit [Aug] ... 8:30a |
